To Our Shareholders
and Investors

• October 02, 2025

  R & D
  Brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne Muscular Dystrophy: Presenting 3.5-Year Clinical Trial Data at the World Muscle Society 2025 Congress
• September 30, 2025

  R & D
  Orphan Drug Designation granted to Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis in Japan
• September 19, 2025

  Pharmaceuticals
  Lilly's antineoplastic agent Jaypirca® 50 mg and 100 mg tablets obtains additional approval as a treatment for relapsed or refractory chronic lymphocytic leukemia resistant or intolerant to other BTK inhibitors
• September 19, 2025

  R & D
  FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy

Upcoming Events

• August 07, 2025
  FY2025 1st Qtr results announcement
• August 07, 2025
  Conference Call(Q1/FY2025)
• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1 MB
• May 08, 2025
  FY2024 Annual results announcement PDF1.9 MB
• February 18, 2025
  R&D Meeting PDF1.7 MB